Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE was delisted on the 3rd of May, 2023.
83 hedge funds and large institutions have $365M invested in Jounce Therapeutics, Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 37 increasing their positions, 15 reducing their positions, and 11 closing their positions.
147% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 15
64% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 11
53% more capital invested
Capital invested by funds: $239M → $365M (+$126M)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
9% more funds holding
Funds holding: 76 → 83 (+7)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $173K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$6.41M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$5.28M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$4.3M |
| 4 |
Millennium Management
New York
|
+$2.74M |
| 5 |
JP Morgan Chase
New York
|
+$1.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.47M |
| 2 |
AC
Ascend Capital
Orinda,
California
|
-$2.81M |
| 3 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
-$2.02M |
| 4 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
-$1.87M |
| 5 |
UBS AM
Chicago,
Illinois
|
-$1.79M |
JNCE Hedge Fund Activity: Q4 2017 in Review
83 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Jounce Therapeutics, Inc. Common Stock (JNCE) for Q4 2017, worth a combined $365M — up 53% from $239M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new JNCE positions and 11 closed out — a net gain of 7 holders — while 37 added to existing stakes and 15 trimmed.
The largest buyer was BlackRock, adding an estimated $6.41M. The largest seller was Fidelity Investments, cutting an estimated $9.47M.
- 83 institutional investors held Jounce Therapeutics, Inc. Common Stock (JNCE) as of Q4 2017, up from 76 in Q3 2017.
- Funds reported $365M of Jounce Therapeutics, Inc. Common Stock stock for Q4 2017, up 53% quarter-over-quarter.
- 18 funds opened new Jounce Therapeutics, Inc. Common Stock positions in Q4 2017 and 11 closed out, a net change of +7 holders.
- The largest Jounce Therapeutics, Inc. Common Stock buyer in Q4 2017 was BlackRock, an estimated $6.41M added.
- The largest Jounce Therapeutics, Inc. Common Stock seller in Q4 2017 was Fidelity Investments, an estimated $9.47M sold.
Based on aggregated 13F filings for Q4 2017.